TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis
Journal of Experimental & Clinical Cancer Research volume 37, Article number: 188 (2018)
Over the last two or three decades, the pace of development of treatments for osteosarcoma tends has been slow. Novel effective therapies for osteosarcoma are still lacking. Previously, we reported that tumor-suppressing STF cDNA 3 (TSSC3) functions as an imprinted tumor suppressor gene in osteosarcoma; however, the underlying mechanism by which TSSC3 suppresses the tumorigenesis and metastasis remain unclear.
We investigated the dynamic expression patterns of TSSC3 and autophagy-related proteins (autophagy related 5 (ATG5) and P62) in 33 human benign bone tumors and 58 osteosarcoma tissues using immunohistochemistry. We further investigated the correlations between TSSC3 and autophagy in osteosarcoma using western blotting and transmission electronic microscopy. CCK-8, Edu, and clone formation assays; wound healing and Transwell assays; PCR; immunohistochemistry; immunofluorescence; and western blotting were used to investigated the responses in TSSC3-overexpressing osteosarcoma cell lines, and in xenografts and metastasis in vivo models, with or without autophagy deficiency caused by chloroquine or ATG5 silencing.
We found that ATG5 expression correlated positively with TSSC3 expression in human osteosarcoma tissues. We demonstrated that TSSC3 was an independent prognostic marker for overall survival in osteosarcoma, and positive ATG5 expression associated with positive TSSC3 expression suggested a favorable prognosis for patients. Then, we showed that TSSC3 overexpression enhanced autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway in osteosarcoma. Further results suggested autophagy contributed to TSSC3-induced suppression of tumorigenesis and metastasis in osteosarcoma in vitro and in vivo models.
Our findings highlighted, for the first time, the importance of autophagy as an underlying mechanism in TSSC3-induced antitumor effects in osteosarcoma. We also revealed that TSSC3-associated positive ATG5 expression might be a potential predictor of favorable prognosis in patients with osteosarcoma.
Osteosarcoma is the most frequent type of primary malignancy of bone and is also the second most common cause of cancer-related death in young adolescents and children [1, 2]. In recent years, given the combination of chemotherapy and surgery as a primary treatment for osteosarcoma, the five-year survival rate has increased to approximately 65–70% for no distant metastasis disease. However, despite progress of in surgical techniques and chemotherapeutic drugs, the five-year survival rate remains poor because osteosarcoma is highly malignant with highly aggressive behavior and shows resistance to chemotherapies, resulting in a five-year survival rate for early lung metastatic patients of only 20% [3, 4]. Over the last two or three decades there have been few developments in the treatment of osteosarcoma. Thus, novel effective therapies for osteosarcoma are still lacking and are urgently required.
Genomic imprinting is an epigenetic form of genetic regulation that results in monoallelic gene expression (maternal or paternal). It is widely accepted that genomic imprinting of tumor suppressor genes contributes to tumor susceptibility because mutation of only one allele is needed . Meanwhile, genomic imprinting, as a form of epigenetic and reversible gene control, can be altered by epigenetic drugs, which highlights a new potential treatment of cancer. Tumor-suppressing STF cDNA 3 (TSSC3), also known as PHLDA2, IPL or BWR1C, is located on chromosome 11p15, a tumor suppressor region, and is the first identified apoptosis-related imprinted gene . Our group revealed that TSSC3 expression is downregulated in osteosarcoma cells, suggesting it as a promising therapeutic target for osteosarcoma . Furthermore, we demonstrated that TSSC3 functions as a tumor suppressor gene, inducing apoptosis, and suppressing tumorigenesis and metastasis in osteosarcoma, and is associated with favorable overall survival (OS) [4, 8,9,10,11]. Despite these findings, the underlying mechanism by which TSSC3 suppresses tumorigenesis and metastasis in osteosarcoma is incompletely understood.
Autophagy is an essential and highly conserved cellular process that targets selective proteins and abnormal organelles for lysosomal degradation . The role of autophagy in cancer is controversial. On the one hand, autophagy can function as a cytoprotective response to chemotherapeutic drugs in cancer cells and promotes metastasis through facilitating the mobility and anoikis resistance of tumor cells [13,14,15,16,17]. On the other hand, numerous studies have demonstrated that autophagy can induce autophagic cell death, cell proliferation inhibition, and oncoproteins degradation to suppresses tumorigenesis, impede metastasis, and even enhance chemosensitivity [18,19,20,21,22,23]. Recently, it has been revealed that autophagy could be regulated by imprinted genes in some cancer cells, such as ovarian cancer cells  and bladder cancer cells . However, the connection between autophagy and imprinted gene in osteosarcoma is less explored. More recently, PHLDA1, the homologous gene of TSSC3 has been demonstrated to trigger autophagy . Moreover, the PI3K/Akt/mTOR signaling pathway, which is a classical pathway that modulates cell proliferation, apoptosis resistance, and tumorigenesis, is reported to be involved in the regulation of autophagy in several human tumors cells [26, 27] and can be activated by the Src-family kinases . Our previous studies found that TSSC3 could inhibit the phosphorylation of both Src and Akt in osteosarcoma cells [10, 11]; therefore, we speculated that autophagy might be involved in the anti-tumor effect of TSSC3.
In the present study, we investigated the correlation between TSSC3 and autophagy-related gene 5 (ATG5) protein expression (one of the key proteins for the formation of autophagosomes)  in human osteosarcoma tissues and their prognostic value in osteosarcoma. Furthermore, we observed enhanced autophagy flux in TSSC3 overexpressing osteosarcoma cells and demonstrated that TSSC3-induced impairment of tumorigenesis and metastasis in osteosarcoma cells was reduced when autophagy was inhibited using chloroquine (CQ) or under conditions of stable knockdown of ATG5 by lentiviral vectors in vitro and in vivo. In addition, the Src-mediated PI3K/Akt/mTOR signaling pathway was found to be involved in TSSC3-induced autophagy. To the best of our knowledge, no previous study has demonstrated the correlation between TSSC3 and autophagy. The findings of this study provide novel insights into the underlying mechanism by which TSSC3 suppresses tumorigenesis and metastasis in osteosarcoma by highlighting the role of autophagy.
Specimens were obtained from 58 patients with histopathologically confirmed osteosarcoma with no preoperative anticancer treatment from Southwest Hospital and Xinqiao Hospital, Third Military Medical University (TMMU), Chongqing, China between February 2011 and November 2015. The last follow-up time was November 2017. The clinicopathological features of the patients are listed in Table 1. Two certified pathologists classified all the specimens as high-grade osteosarcoma. Lung metastasis and local recurrence were diagnosed by both imaging and pathology. The surgical margins and stage were classified according to the Enneking system. Patients with primary osteosarcoma were classified as with or without developed distant metastasis at diagnosis or after surgery. Written informed consent for the experimental studies was obtained from the patients or their guardians. All experiments were approved by the Institutional Ethics Committee of TMMU.
The details of the human benign bone and soft tissue tumor specimens are show in Additional file 1.
The human osteosarcoma cell line SaOS2 was obtained from Cellcook Biological Technology Co., Ltd. (Guangzhou China). The malignant transformed hFOB1.19 cell line (MTF cells) was produced in our laboratory, as previously reported . All the cells were maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM, Hyclone, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, BI, Kibbutz Beit Haemek, Israel) and 1% penicillin-streptomycin (Hyclone). All the cells were cultured at 37 °C in 5% CO2 and humidified atmosphere.
Cells were treated with pYEEI (100 mM, Src activator, Enzo Life Science, The Netherlands), BEZ235 (500 nM, PI3K inhibitor, MedChem Express, USA) or IGF-1 (100 ng/ml, Akt activator, R&D System, USA), chloroquine (CQ, 8 μM autophagy flux inhibitors, Sigma-Aldrich, USA) for 12 h, separately or in combination.
The pLVX-mCMV-ZsGreen expressing lentiviral vector for TSSC3 and the control was synthesized and obtained from Chongqing Maobai Technology Co., Ltd. (Maobai, Chongqing, China) and the coding sequence of TSSC3 was amplified using the primers 5′-CCGGAATTCGCCACCATGAAATCCCCCGACGAGGTGCTAC-3′ and 5′-CGCGGATCCTCACTTATCGTCGTCATCCTTGTA-3′. The short hairpin RNA (shRNA) in the pHBLV-U6-Puro lentiviral vector targeting ATG5 and its control (scrambled) were purchased from Hanbio Biotechnology Co., Ltd. (Hanbio, Shanghai, China). MTF and SaOS2 cells were infected with the lentivirus vectors according to the manufacturer’s instructions and as previously described [9, 10]. The shRNA target sequences are listed in Additional file 2: Table S1). The overexpression and knockdown function was verified using quantitative real-time PCR and western blotting analysis.
Cell proliferation, cell viability, and colony formation assays
For the cell proliferation assay, a cell light 5-ethynyl-2′-deoxyuridine (EdU) imaging kit (C0075S, Beyotime, Shanghai, China) was used according to the manufacturer’s instructions (Edu; 10 μM, 2 h, for MTF cells and 20 μM, 2 h, for SaOS2 cells). Cells were observed under an inverted phase contrast fluorescence microscope (Olympus, Tokyo, Japan). Cell counting kit-8 (CCK8, C0038, Beyotime) and colony formation assays were carried as described previously [8, 30].
Transmission electronic microscopy
The transmission electron microscopy (TEM) assay was performed as previously described . Briefly, cells (1 × 106) were harvested after transfection with lentivirus overexpressing TSSC3 (overTSSC3) and its control (overCtrl), while fresh tissues were dissected, fixed with 4% glutaraldehyde in phosphate-buffered saline (PBS) at 4 °C overnight, post-fixed in 1% osmium tetroxide, dehydrated with ethanol, embedded in Epon, and then stained with aqueous uranyl acetate and lead citrate before being observed. Images were acquired using a HT7700 electron microscope (HITACHI, Tokyo, Japan). The number of autophagic vacuoles (AVs), including autophagosomes and autolysosomes, in each cell was quantified in 20 randomly selected cells of each group .
Quantitative real-time PCR analysis and western blot analysis
Quantitative real-time PCR (qPCR) and western blotting analyses were performed as previously described . The primers used in this study are listed in Additional file 2: Table S2 and the details of western blotting are listed in Additional file 1.
Immunofluorescence, apoptotic analysis, histology, and immunohistochemistry
Wound healing and Transwell assays
Wound healing and Transwell assays were performed as previously described [4, 11]. Briefly, after appropriate treatments, cells were seeded in 6-well plates and cultured until they reached 90% confluence. A 10-μl micropipette tip was used to make a wound. Cells were monitored at 0 h and 48 h after scratching and images of wound healing were captured (magnification of 100×) using a inverted phase contrast light microscope (Olympus, Tokyo, Japan) with DP Controller software (Olympus Life Science, Tokyo, Japan). Cell migration was quantified by measuring the wound healing index; i.e., the wound area healed by the cells at 48 h after scratching relative to the wound area at 0 h, using ImageJ software. For the Transwell migration or invasion assays, cells were resuspended in DMEM without serum and seeded into the upper chamber of 8-μm Transwell filters (Merck Millipore, Berlin, Germany). The invasion assay was performed using filters pre-coated in 1:3 diluted matrigel (BD Biosciences, Bedford, MA, USA) while the migration assay was not. DMEM containing 15% FBS was added to the lower chambers (24-well plate) and the cells were incubated 16 h for the migration assay and 24 h for the invasion assay. The invaded or migrated cells were quantified after 0.1% crystal violet staining in five randomly selected fields (magnification of 200×).
Xenograft models were generated in 6-week-old female nude mice (Laboratory Animal Center, Xinqiao Hospital, TMMU). Eighteen Mice were randomly divided into three groups (six for overCtrl and scrambled MTF cells; six for overTSSC3 and scrambled MTF cells; and six for overTSSC3 and shATG5 MTF cells) and weighed every four days. Cells suspensions of 4 × 106 cells/ml in PBS were injected subcutaneously into a single side of the infra-axillary of each mouse in a volume of 0.1 ml. Xenografts were observed and measured every three days. The volume of xenografts were calculated as V (mm3) =1/2 × (length × width2) . Mice were sacrificed at 20 days after injection and tumors were harvested and measured. A small part of tumors were excised and fixed with 4% glutaraldehyde quickly on ice for TEM. The remainder was fixed with 10% neutral buffered formalin, sliced, subjected to hematoxylin and eosin (H&E) staining, and further analyzed by immunohistochemistry (IHC).
In vivo lung metastasis model
Twenty-one nude mice were randomly divided into three groups as mentioned above. Cell suspensions of 5 × 107 cells/ml were injected into the tail vein of 4-week-old female nude mice (Laboratory Animal Center, Xinqiao Hospital, TMMU) in a volume of 100 μl. The mice were evaluated every two days for weight and emaciation incapacitating tumor burden. Natural deaths of the nude mice were recorded to calculate the lifetime at 38 days after injection. The surviving nude mice were sacrificed at 38 days. All the lungs were resected and fixed in 10% neutral buffered formalin, and the fixed lungs were embedded in paraffin, sectioned, and stained with H&E. Microscopic lung metastases were counted under a light microscope after H&E staining. Five discontinuous and deep sections were used to define whether there was a metastasis nodule in the fixed lungs and the number of lung metastasis nodules was counted in one section with the most nodules.
All the animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Xinqiao Hospital, TMMU, and were performed according to the Guide for the Care Use of Laboratory Animals.
Quantitative data are presented as the mean ± SD. Quantitative data were analyzed using unpaired Student’s t-tests for two groups and analysis of variance (ANOVA) with Bonferroni’s multiple comparisons for three or more groups. Categorical data were analyzed using the Chi-squared test or Fisher’s exact test, and Spearman rank correlation coefficients. Survival analysis was carried out using the Kaplan–Meier method with the log-rank test. The independent prognostic factors were determined by Cox regression analysis. P < 0.05 was considered statistically significant. All analyses were performed using SPSS 20.0 software (version 20.0, SPSS Inc., Chicago, IL, USA) or GraphPad Prism (version 7.00, GraphPad Software, Inc., San Diego, CA, USA). In Vitro experiments were performed at least triplicate.
ATG5 expression correlates positively with TSSC3 expression in osteosarcoma tissues
Previously, we proved that TSSC3 mRNA expression is decreased in human osteosarcoma tissues compared with that in non-tumor tissues . To examine the correlation between TSSC3 and autophagy, we first applied immunohistochemical staining to examine the TSSC3, ATG5, and P62 expression in human benign bone and soft tissue tumors, and osteosarcoma. We observed higher rate of TSSC3 and ATG5 positivity in fibrous dysplasia and osteoblastoma compared with that in osteosarcoma (P < 0.05), while the positive rate of P62 expression was lower but not statistically significant (P > 0.05) in fibrous dysplasia and osteoblastoma compared with that in osteosarcoma (Additional file 3: Figure S1 a-c). The results showed that TSSC3 and autophagy-related proteins expression were in good agreement with various tendencies of benign bone and soft tissue tumors and osteosarcoma suggesting a potential correlation between them in osteosarcoma. To further confirm this, 58 human osteosarcoma tissues were used to investigate the relevance of TSSC3, ATG5, and P62 expression in vivo. The representative images of positive or negative IHC staining of TSSC3, ATG5, and P62 are shown in Fig. 1a. Interestingly, a higher IHC score for ATG5 was found in osteosarcoma patients with positive expression of TSSC3 (Fig. 1b). Further analysis demonstrated that the TSSC3 expression is positively correlated with that of ATG5. (Additional file 2: Table S3). However, we failed to detect a significant correlation between TSSC3 and P62 expression (Fig. 1c and Additional file 2: Table S3). Overall, these data suggested that ATG5 expression positively correlated with TSSC3 expression in osteosarcoma tissues.
Positive expression of ATG5, associated with positive TSSC3, predicts a favorable prognosis of osteosarcoma
We then used IHC staining of above tissues to investigate the correlations between TSSC3, ATG5, and P62 expression and clinicopathological features of osteosarcoma. Among the 58 patients, there were 34 males and 24 females. The median age was 22 years old (range: 8–59 years old). The follow-up time ranged from 4 (death) to 80 months. Twenty-two patients had local recurrence after chemotherapy and surgery of the primary osteosarcoma, 12 patients had lung metastasis at diagnosis, and eight more patients developed lung metastasis after the treatment (Table 1). Moreover, we found that expression of TSSC3 was significantly associated with a lower local recurrence rate (P < 0.05), but not with age, sex, stage, location, size, and pathological subtype. The rate of TSSC3 positivity was 36.8% (14/38) in osteosarcoma without metastasis and 15.0% (3/20) in osteosarcoma with metastasis; however, the decrease was not significant (P = 0.082) (Table 1). Surprisingly, neither the expression of ATG5 nor P62 seemed to be associated with the clinicopathological features of osteosarcoma (Table 1). As expected, Kaplan-Meier curves showed positive expression of TSSC3 was significantly related to an improved OS (Fig. 1d), while the differential expression of ATG5 and P62 had no notable impact on OS (Fig. 1e). Furthermore, TSSC3 protein expression, tumor size, and metastasis were validated to be independent prognostic markers for OS of osteosarcoma by univariate and multivariate Cox regression (Additional file 2: Table S4 and Table 2). We further observed that positive expression of TSSC3 and ATG5 was significantly associated with an earlier Enneking stage and there were markedly lower metastasis and recurrence rate (7.1 and 14.3%) for positive ATG5 expression compared to negative ATG5 expression (66.7 and 33.3%) in TSSC3(+) osteosarcoma; however, these differences were not statistically significant (Additional file 2: Table S5). Thus, we inferred that positive ATG5 expression in patients with TSSC3(+) osteosarcoma might suggest a favorable prognosis. To test this hypothesis, Kaplan–Meier analysis showed the patients with positive expression of both TSSC3 and ATG5 displayed a more favorable OS (Fig. 1f). Taken together, these results showed that TSSC3 is an independent prognostic marker for OS and positive expression of both TSSC3 and ATG5 is a potential predictor of favorable prognosis in osteosarcoma.
TSSC3 overexpression enhances autophagic flux in osteosarcoma cells in vitro
We found ATG5 expression is positively correlated with TSSC3 expression in osteosarcoma samples, and the relationship between TSSC3 and autophagy had never been reported before. Therefore, we examine the effect of TSSC3 in regulating autophagy in osteosarcoma cells. First, we stably overexpressed TSSC3 using lenti-overTSSC3 in MTF and SaOS2 cells and examined the formation of AVs by using TEM. The results demonstrated that there was an increased number of large diameter autophagosomes and autolysosomes in MTF or SaOS2 cells transfected with lenti-overTSSC3 transfected (Fig. 2a). Consistent with this, western blotting analysis revealed an accumulation of ATG5, BECN1, and lipid-bound LC3-II in TSSC3-overexpressing cells (Fig. 2b), which indicated an increase in the synthesis of autophagosomes . In complementary experiments, immunofluorescence assays demonstrated that BECN1, ATG5, and LC3B levels were significantly increase in TSSC3-overexpressing cells (Additional file 3: Figure S2 a). In addition, overexpression of TSSC3 in osteosarcoma cell lines increased BECN1 and ATG5 mRNA levels (Additional file 3: Figure S2b). Furthermore, to investigate the effect of TSSC3 on autophagic flux, the expression of P62, also known as sequestosome 1 (SQSTM1), a substrate of autophagy , was examined. As expected, TSSC3 overexpression decreased P62 protein levels (Fig. 2b), suggesting enhanced autophagic flux. To verify this result, the lysosomal autophagy inhibitor CQ was used, which resulted in increased LC3-II and P62 accumulation in TSSC3-overexpressing cells (Fig. 2c), supporting the notion that TSSC3 overexpression did not block autophagic flux. Taken together, these data suggested that TSSC3 overexpression induced autophagy and enhanced autophagic flux in osteosarcoma cells in vitro.
TSSC3-mediated autophagy contributes to TSSC3-induced inhibition of malignant proliferation of osteosarcoma cells
Autophagy has been reported as a tumorigenesis suppressor in some situations [35, 36] and we have found TSSC3 overexpression enhanced autophagy flux and inhibited cell proliferation (Additional file 3: Figure S3 a) in osteosarcoma cells . Thus, to determine whether TSSC3-induced inhibition of osteosarcoma malignant proliferation was related to autophagy, we applied the CCK-8 assay to detect the cell viability with or without TSSC3-overexpression, with or without autophagy suppression by CQ. We found that overexpression of TSSC3 significantly decreased the cell viability of MTF and SaOS2 cells, and no obvious cytotoxicity was found compared with the control group when the cells were treated with CQ alone. By contrast, CQ significantly blocked the autophagic flux (Additional file 3: Figure S2 c), and cell viability was partly rescued in TSSC3-overexpressed cells when treated with CQ (Fig. 3a). Subsequently, we found that blocking autophagy with CQ attenuated the TSSC3-induced suppression of proliferation and colony-formation ability of MTF and SaOS2 cells, as assessed using EdU and colony formation assays (Fig. 3b and c). These data indicated that TSSC3-induced inhibition of malignant proliferation of osteosarcoma cell lines might be related to autophagy. Moreover, to further confirm this notion, enhanced autophagy was eliminated via ATG5 knockdown using shRNA lentiviruses (two effective sequences were chosen), which were stably transfected into TSSC3-overexpressing cells; western blotting analysis confirmed this result (Fig. 3d). We also found that blocking autophagy (ATG5 knockdown) reduced TSSC3-induced inhibition of cell proliferation and colony-formation ability in MTF and SaOS2 cells (Fig. 3e and f). Accumulating evidence shows that autophagy can promote apoptosis to suppress tumor progression . Therefore, to determine whether TSSC3-mediated autophagy could suppress malignant proliferation depending on apoptosis in osteosarcoma cell lines, Hoechst and Annexin V-PE/7-AAD staining were used. As shown in Additional file 3: Figure S3 b and c, inhibition of autophagy by CQ partly abrogated TSSC3-induced apoptosis in SaOS2 cells, which was consistent with the markedly upregulation of cleaved caspase-3 and Bax, and reduced Bcl2 (Additional file 3: Figure S3 d). Intriguingly, autophagy inhibition had no visible effect of TSSC3-induced apoptosis in the MTF cell line (Additional file 3: Figure S3 b-d). These differences may be derived from the genetic background of the cell lines. Collectively, these results suggested that TSSC3-mediated autophagy contributes to the anti-osteosarcoma effect of TSSC3 by suppressing cell malignant proliferation, which may not completely depend on autophagy-triggered apoptosis.
Crucial involvement of autophagy in TSSC3-mediated tumorigenesis in osteosarcoma cells in vivo
Having shown that TSSC3 mediates autophagy and induces inhibition of malignant proliferation of osteosarcoma cells in vitro, it was important to determine whether these effects could be detected in vivo. We established subcutaneous xenograft models by stably transfecting MTF cells into athymic nude mice. Then, we found that TSSC3 overexpression significantly reduced tumorigenesis, as reflected by the tumor size, volume, body weight, and tumor weight of the xenograft tumors. However, knockdown of ATG5 restored tumorigenesis in TSSC3-overexpressing cells (Additional file 3: Figure S4 a-b and Fig. 4a-b). Moreover, that overexpression of TSSC3 enhanced autophagy and knockdown of ATG5 blocked TSSC3-induced autophagy were further confirmed in vivo using TEM (Fig. 4c) and IHC staining of TSSC3 and autophagy related proteins of human xenograft tumor tissues (Fig. 4d and Additional file 3: Figure S4c). As expected, the rate of positive Ki67 IHC staining was high in the control groups, decreased in the TSSC3-overexpressing group, and restored in the TSSC3-overexpressing and ATG5-knockdown groups, suggesting that autophagy contributes to TSSC3-induced inhibition of malignant proliferation in vivo (Additional file 3: Figure S4d and Fig. 4e). Thus, all of the vitro and in vivo results indicated that TSSC3-induced autophagy plays a crucial role in TSSC3-mediated tumorigenesis in osteosarcoma cells.
TSSC3 inhibits osteosarcoma cells migration and invasion associated with autophagy
Metastasis is a major factor predicting poor prognosis in patients with osteosarcoma  and autophagy depends on an environment that may limit the invasion and dissemination of tumor cells from a primary site [21, 36]. We found that positive expression of both TSSC3 and ATG5 is significantly associated with an improved prognosis and correlated negatively with metastasis in human osteosarcoma; therefore, we speculated that TSSC3-induced autophagy might have an effect on the regulation of osteosarcoma cell metastasis. To confirm this speculation, we used wound healing and Transwell assays. The results showed that TSSC3 overexpression significantly decreased the motility and invasive ability of MTF and SaOS2 cells, but had no significant effect when the cells were treated with CQ alone, compared with that in the control group. Although the inhibitory effects of TSSC3 overexpression on cell motility and invasive ability were markedly attenuated by CQ treatment (Fig. 5a and b), knockdown of I in TSSC3-overexpressing MTF and SaOS2 cells significantly improved cell motility and invasion (Fig. 5c and d). Thus, these results confirmed the findings that TSSC3 overexpression-induced autophagy suppresses osteosarcoma cell metastasis in vitro. To further investigate the mechanism, we observed that the epithelial cell marker E-cadherin was upregulated in TSSC3-overexpressing SaOS2 cells (but not in MTF cells), whereas the expression levels of mesenchymal markers N-cadherin, Vimentin, and MMP2 were inhibited. These protein expression levels did not increase significantly when the cells were treated with CQ alone to block autophagy. However, interestingly, the N-cadherin, Vimentin, and MMP2 levels increased markedly when TSSC3-overexpressing MTF and SaOS2 cells were treated with CQ (a decrease in the E-cadherin level was also detected in TSSC-overexpressing SaOS2 cells) (Fig. 5e and f). The epithelial-mesenchymal transition (EMT) is a metastatic behavior of cancer cells . Thus, the impairment of MTF and SaOS2 cell migration and invasion might be caused by inhibition of the EMT, dependent on TSSC3 overexpression-induced autophagy.
Autophagy contributes to TSSC3-induced lung metastasis suppression in vivo
To further investigate whether autophagy contributes to TSSC3-induced suppression of metastasis in osteosarcoma, we established a lung metastasis model in vivo by injecting stably transfected MTF cells into the tail vein of athymic nude mice. We found that overexpression of TSSC3 notably reduced the ability of MTF cells to induce lung metastases, as reflected by the decreased incidence and number of metastatic nodules and the increased survival time of the mice. However, knockdown of ATG5 restored the ability of TSSC3-overexpressing cells to establish lung metastases (Fig. 6a-c and Additional file 3: Figure S6b). In addition, using IHC staining, the metastatic nodules were negative for E-cadherin and CK18, but positive for Vimentin, indicative of a mesenchymal origin (Additional file 3: Figure S6a). Consistent with these findings, the expression change of E-cadherin and Vimentin in subcutaneous xenograft tumors induced using transfected cells were measured using IHC staining (Fig. 6d and e), which indicated that TSSC3-induced autophagy blocked the EMT of osteosarcoma cells in vivo. These results, together with our in vitro findings, highlighted a functional role for autophagy in the regulation of TSSC3-induced lung metastasis suppression in osteosarcoma.
TSSC3 overexpression induces autophagy in osteosarcoma cells via inactivating the Src-mediated PI3K/Akt/mTOR pathway
Our previous studies suggested TSSC3 expression might regulate the phosphorylation of Src and Akt. In view of the important role of the PI3K/Akt/mTOR pathway in autophagy regulation  and the role of Src in activating the PI3K/Akt pathway [11, 28], to determine how TSSC3 mediated autophagy in osteosarcoma, we first measured Src, Akt, mTOR, and their phosphorylation levels in TSSC3-overexpressing MTF and SaOS2 cells. The results showed that overexpression of TSSC3 did not affect the total Src, Akt and mTOR levels, but significantly decreased the levels of their phosphorylated forms (Fig. 7a), which suggested that the Src and PI3K/Akt/mTOR pathways might be involved in TSSC3-induced autophagy. Then, we applied IGF-1 and p-YEEI for Src and PI3K/Akt pathway activation, separately or in combination, to further identify whether the Src and PI3K/Akt/mTOR signaling pathways underlie TSSC3-mediated autophagy. TSSC3 overexpression inhibited Src and PI3K/Akt/mTOR activity, increased the levels of ATG5 and LC3-II, and decreased P62 expression. Following p-YEEI or IGF-1 treatment, the Src or PI3K/Akt/mTOR pathway was significantly activated, remarkably reversing the effect of TSSC3 overexpression on autophagy related proteins in MTF and SaOS2 cells. This implied that PI3K/Akt/mTOR or Src inhibition triggered autophagy in TSSC3-overexpressing cells (Fig. 7b). We also found that the PI3K/Akt/mTOR pathway was activated when the cells were treated with p-YEEI, but no obvious increase of Src phosphorylation was found after applying IGF-1. This result suggested that TSSC3-induced PI3K/Akt/mTOR pathway inhibition is Src-dependent. Furthermore, we applied p-YEEI and BEZ235 together to activate Src signaling and inhibit PI3K/Akt/mTOR pathway. The result indicated that inhibition of Src phosphorylation without PI3K/Akt/mTOR inactivation could not decrease the ATG5 and LC3-II levels or increase the P62 levels in TSSC3-overexpressing MTF and SaOS2 cells (Fig. 7b). Taken together, these results allowed us to conclude that TSSC3 overexpression induces autophagy in osteosarcoma cells by inactivating the Src-mediated PI3K/Akt/mTOR pathway.
TSSC3, a maternally expressed imprinted gene that has a potential growth inhibitory effect, was reported to loss its expression in several cancers, including osteosarcoma . In our previous work, we demonstrated that TSSC3 acts as a tumor suppressor gene in osteosarcoma [4, 8,9,10,11]. Moreover, Enhancer of zeste homolog 2 (EZH2) was found to be involved in loss of TSSC3 expression  and the expression of TSSC3 could be altered by 5-Aza-CdR (a DNA methyltransferase inhibitor) treatment in osteosarcoma cells . Although, many anti-tumor effects were found to be associated with TSSC3 in osteosarcoma, the mechanism underlying these effects remain poorly understood. In the present study, we demonstrated that TSSC3 expression associated with ATG5 expression might be a favorable prognostic marker of osteosarcoma. We provided further evidence that TSSC3 overexpression induces autophagy, likely via the Src-mediated PI3K/Akt/mTOR pathway, and autophagy, at least partially, contributes to TSSC3-induced tumorigenesis and metastasis suppression in osteosarcoma, both in vitro and in vivo.
Accumulating evidence suggests that autophagy is correlated with progression and patient outcome after treatment in diverse types of cancer [12, 29, 36]. ATG5 and P62, as essential autophagy-related regulatory proteins, have recently been identified as novel potential prognostic biomarkers for colorectal, breast, cutaneous, and other types of cancer [38, 40,41,42,43,44,45,46]. However, with regard to the prognostic impact of ATG5 and P62 immunohistochemistry in various types of cancers, there are considerable discrepancies in the previous reports. For example, high expression of ATG5 suggested a superior prognosis in breast cancer, colorectal cancer, and early-stage melanoma [40,41,42], but indicated a poor outcome in oral squamous cell carcinoma . High expression of P62 is always related to an inferior prognosis in breast cancer , but might lead to a longer disease-free survival in stage II melanomas . Besides, these proteins may not have a prognostic value in some situations . Thus, many discrepancies remain, and there are few studies on the expression dynamics of ATG5 and P62 and their prognostic roles in osteosarcoma. In the present study, we found that ATG5 was significantly downregulated, together with an accumulation of P62 in osteosarcoma tissues. This supports the notion that autophagy is a protective player in early tumorigenesis and P62 is involved in Ras-induced tumorigenesis [29, 34]. To the best of our knowledge, this is the first study to investigate the expression dynamics of ATG5 and P62 in human osteosarcoma tissues. Unfortunately, despite their notable change in expression in osteosarcoma, we failed to demonstrate an association between ATG5 or P62 with the characteristics of the patients with osteosarcoma, and neither ATG5 nor P62 seemed to be reliable prognostic biomarkers for osteosarcoma; however, this requires further validation because of our limited sample sample size. Moreover, TSSC3 was validated to be negatively associated with local recurrence and might be an independent prognostic marker for OS in osteosarcoma patients, which was similar to the observations in previous studies [11, 47]. Importantly, we demonstrated that ATG5 expression was closely and positively correlated with TSSC3 expression in osteosarcoma for the first time, indicating there was a potential correlation between TSSC3 and autophagy. More importantly, we observed that among the patients with positive TSSC3 expression, the subset with positive ATG5 expression correlated with an earlier Enneking stage and displayed a significantly better OS compared to those with negative expression of ATG5. Thus, positive ATG5 expression could be a potential predictor of favorable prognosis in patients with TSSC3(+) osteosarcoma.
In the current study, we demonstrated that TSSC3 overexpression enhanced autophagy flux in osteosarcoma cells, which was consistent with the results that ATG5 (widely known as a key protein for the formation of autophagosomes) expression was positively correlated with TSSC3 expression in human osteosarcoma tissues. PHLDA1, a homologous gene of TSSC3 (PHLDA2) has been reported to regulate autophagy in breast cancer and neuroblastoma cells [25, 48], which also suggested that TSSC3 might have the ability to regulate autophagy. As mentioned in the introduction, autophagy displays a dynamic and complicated function in cancer [21, 29, 35, 36] and can suppress tumorigenesis and metastasis in response to some stressors [2, 20, 22, 31, 37, 44]. Our findings suggested that autophagy contributes to TSSC3-mediated inhibition of tumorigenesis and metastasis in in vitro and in vivo models of osteosarcoma. EMT is widely known as an essential process during cancer progression and promotes the metastatic potential of cancer cells . There is evidence that autophagy impairs the EMT by promoting Snail protein degradation  and weakening the stabilization of the Twist 1 protein by attenuating P62 expression . Although osteosarcoma is a mesenchymal type sarcoma, we found previously that an EMT-like process exists in osteosarcoma cells that facilitates the metastatic phenotype and could be regulated by TSSC3 . In the current study, our observations indicated that autophagy contributes to TSSC3-induced impairment of the EMT-like process in osteosarcoma cells. However, the mechanism by which TSSC3-induced autophagy impairs this EMT-like process in osteosarcoma cells remains unclear and further studies are need to investigate it. Autophagy can induce and contribute to apoptosis . Interestingly, in our study, inhibition of autophagy inhibition displayed an opposite effect of TSSC3-induced apoptosis between MTF and SaOS2 cell lines. Similarly, autophagy inhibition was reported to have an opposing impact on the response of two osteosarcoma cell lines following camptothecin treatment . Thus, we speculated that the partial autophagic effect not only varies for different cancers, but also in different cell lines.
As a member of phosphatidylinositol 3-kinase-related kinases (PIKKs), mTOR is one of the key regulators of mammalian cell metabolism and is the main downstream target of the PI3K/Akt signaling pathway . Numerous reports have highlighted the importance of mTOR and its downstream target p70S6K in regulating autophagy [26, 27]. Previously, we reported that TSSC3 interacts with RanBP9 bound to Src to prevent its phosphorylation, which further abrogated Src-dependent Akt pathway activation . It is reported that the homologous genes of TSSC3, for example PHLDA1 and PHLDA3, are involved in the regulation of mTOR and p70S6K phosphorylation . Here, we demonstrated that TSSC3 overexpression also prevented mTOR phosphorylation, and that suppression of Akt/mTOR phosphorylation is a critical factor regulating in TSSC3-induced autophagy is Src-dependent. Collectively, these findings provide a more detailed understanding of the mechanism of TSSC3’s antitumor effects (Fig. 7c).
Taken together, we demonstrated, for the first time, that TSSC3 induces autophagy via inhibiting the Src-dependent PI3K/Akt/mTOR pathway in osteosarcoma. Furthermore, we found that TSSC3-induced autophagy contributes to suppressing tumorigenesis and metastasis in osteosarcoma, both in vitro and in vivo. In addition, TSSC3 is an independent prognostic marker for OS in patients with osteosarcoma, and TSSC3-associated positive ATG5 expression might be a potential applicable predictor of favorable prognosis. Therefore, our results highlight the importance of autophagy in TSSC3-induced antitumor effects and provide important insights into the underlying mechanism of TSSC3-induced antitumor effects.
- ATG5 :
Autophagy-related gene 5 (ATG5)
- BECN1 :
Beclin1, autophagy-related gene 6
- CQ :
Mammalian target of rapamycin
Pleckstrin homology-like domain, family A, member 2
- TSSC3 :
Tumor-suppressing STF cDNA 3
Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res. 2002;397:40–52.
Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010;5:78.
Ta HT, Dass CR, Choong PF, Dunstan DE. Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 2009;28(1–2):247–63.
Lv YF, Dai H, Yan GN, Meng G, Zhang X, Guo QN. Downregulation of tumor suppressing STF cDNA 3 promotes epithelial-mesenchymal transition and tumor metastasis of osteosarcoma by the Wnt/GSK-3beta/beta-catenin/snail signaling pathway. Cancer Lett. 2016;373(2):164–73.
Pulford DJ, Falls JG, Killian JK, Jirtle RL. Polymorphisms, genomic imprinting and cancer susceptibility. Mutat Res. 1999;436(1):59–67.
Lee MP, Feinberg AP. Genomic imprinting of a human apoptosis gene homologue, TSSC3. Cancer Res. 1998;58(5):1052–6.
Li Y, Meng G, Guo QN. Changes in genomic imprinting and gene expression associated with transformation in a model of human osteosarcoma. Exp Mol Pathol. 2008;84(3):234–9.
Dai H, Huang Y, Li Y, Meng G, Wang Y, Guo QN. TSSC3 overexpression associates with growth inhibition, apoptosis induction and enhances chemotherapeutic effects in human osteosarcoma. Carcinogenesis. 2012;33(1):30–40.
Huang Y, Dai H, Guo QN. TSSC3 overexpression reduces stemness and induces apoptosis of osteosarcoma tumor-initiating cells. Apoptosis. 2012;17(8):749–61.
Dai H, Lv YF, Yan GN, Meng G, Zhang X, Guo QN. RanBP9/TSSC3 complex cooperates to suppress anoikis resistance and metastasis via inhibiting Src-mediated Akt signaling in osteosarcoma. Cell Death Dis. 2016;7(12):e2572.
Yan GN, Tang XF, Zhang XC, He T, Huang YS, Zhang X, et al. TSSC3 represses self-renewal of osteosarcoma stem cells and Nanog expression by inhibiting the Src/Akt pathway. Oncotarget. 2017;8(49):85628–41.
Santana-Codina N, Mancias JD, Kimmelman AC. The role of autophagy in Cancer. Annual Review of Cancer Biology. 2017;1(1):19–39.
Peng YF, Shi YH, Ding ZB, Ke AW, Gu CY, Hui B, et al. Autophagy inhibition suppresses pulmonary metastasis of HCC in mice via impairing anoikis resistance and colonization of HCC cells. Autophagy. 2013;9(12):2056–68.
Li B, Wang W, Li Z, Chen Z, Zhi X, Xu J, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 2017;410:212–27.
Kim M, Jung JY, Choi S, Lee H, Morales LD, Koh JT, et al. GFRA1 promotes cisplatin-induced chemoresistance in osteosarcoma by inducing autophagy. Autophagy. 2017;13(1):149–68.
Sharifi MN, Mowers EE, Drake LE, Collier C, Chen H, Zamora M, et al. Autophagy promotes focal adhesion disassembly and cell motility of metastatic tumor cells through the direct interaction of Paxillin with LC3. Cell Rep. 2016;15(8):1660–72.
Zhang C, Zhang X, Xu R, Huang B, Chen AJ, Li C, et al. TGF-beta2 initiates autophagy via Smad and non-Smad pathway to promote glioma cells' invasion. J Exp Clin Cancer Res. 2017;36(1):162.
Hsin MC, Hsieh YH, Wang PH, Ko JL, Hsin IL, Yang SF. Hispolon suppresses metastasis via autophagic degradation of cathepsin S in cervical cancer cells. Cell Death Dis. 2017;8(10):e3089.
Dasari SK, Bialik S, Levin-Zaidman S, Levin-Salomon V, Merrill AH Jr, Futerman AH, et al. Signalome-wide RNAi screen identifies GBA1 as a positive mediator of autophagic cell death. Cell Death Differ. 2017;24(7):1288–302.
Washington MN, Suh G, Orozco AF, Sutton MN, Yang H, Wang Y, et al. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death Dis. 2015;6:e1836.
Kenific CM, Thorburn A, Debnath J. Autophagy and metastasis: another double-edged sword. Curr Opin Cell Biol. 2010;22(2):241–5.
Liu W, Wang X, Wang Y, Dai Y, Xie Y, Ping Y, et al. SGK1 inhibition-induced autophagy impairs prostate cancer metastasis by reversing EMT. J Exp Clin Cancer Res. 2018;37(1):73.
Petherick KJ, Williams AC, Lane JD, Ordonez-Moran P, Huelsken J, Collard TJ, et al. Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62 crosstalk. EMBO J. 2013;32(13):1903–16.
Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, et al. Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. Mol BioSyst. 2013;9(3):407–11.
Durbas M, Horwacik I, Boratyn E, Rokita H. Downregulation of the PHLDA1 gene in IMR-32 neuroblastoma cells increases levels of aurora a, TRKB and affects proteins involved in apoptosis and autophagy pathways. Int J Oncol. 2016;49(2):823–37.
Wang J, Liu X, Hong Y, Wang S, Chen P, Gu A, et al. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma. J Exp Clin Cancer Res. 2017;36(1):96.
Kumar D, Shankar S, Srivastava RK. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway. Cancer Lett. 2014;343(2):179–89.
Van Grol J, Subauste C, Andrade RM, Fujinaga K, Nelson J, Subauste CS. HIV-1 inhibits autophagy in bystander macrophage/monocytic cells through Src-Akt and STAT3. PLoS One. 2010;5(7):e11733.
Liu H, He Z, Simon HU. Protective role of autophagy and autophagy-related protein 5 in early tumorigenesis. J Mol Med (Berl). 2015;93(2):159–64.
Meng G, Lv Y, Dai H, Zhang X, Guo QN. Epigenetic silencing of methyl-CpG-binding protein 2 gene affects proliferation, invasion, migration, and apoptosis of human osteosarcoma cells. Tumour Biol. 2014;35(12):11819–27.
Chen S, Han Q, Wang X, Yang M, Zhang Z, Li P, et al. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway. Cell Death Dis. 2013;4:e842.
Lv YF, Yan GN, Meng G, Zhang X, Guo QN. Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma. Sci Rep. 2015;5:12999.
Naito S, von Eschenbach AC, Giavazzi R, Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986;46(8):4109–15.
Moscat J, Diaz-Meco MT. p62 at the crossroads of autophagy, apoptosis, and cancer. Cell. 2009;137(6):1001–4.
Apel A, Zentgraf H, Buchler MW, Herr I. Autophagy-a double-edged sword in oncology. Int J Cancer. 2009;125(5):991–5.
Towers CG, Thorburn A. Therapeutic targeting of autophagy. EBioMedicine. 2016;14:15–23.
Liu W, Wang X, Liu Z, Wang Y, Yin B, Yu P, et al. SGK1 inhibition induces autophagy-dependent apoptosis via the mTOR-Foxo3a pathway. Br J Cancer. 2017;117(8):1139–53.
Jayachandran A, Dhungel B, Steel JC. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. J Hematol Oncol. 2016;9(1):74.
Li Y, Huang Y, Lv Y, Meng G, Guo QN. Epigenetic regulation of the pro-apoptosis gene TSSC3 in human osteosarcoma cells. Biomed Pharmacother. 2014;68(1):45–50.
Wang L, Yao L, Zheng YZ, Xu Q, Liu XP, Hu X, et al. Expression of autophagy-related proteins ATG5 and FIP200 predicts favorable disease-free survival in patients with breast cancer. Biochem Biophys Res Commun. 2015;458(4):816–22.
Cho DH, Jo YK, Kim SC, Park IJ, Kim JC. Down-regulated expression of ATG5 in colorectal cancer. Anticancer Res. 2012;32(9):4091–6.
Liu H, He Z, von Rutte T, Yousefi S, Hunger RE, Simon HU. Down-regulation of autophagy-related protein 5 (ATG5) contributes to the pathogenesis of early-stage cutaneous melanoma. Sci Transl Med. 2013;5(202):202ra123.
Tang JY, Fang YY, Hsi E, Huang YC, Hsu NC, Yang WC, et al. Immunopositivity of Beclin-1 and ATG5 as indicators of survival and disease recurrence in oral squamous cell carcinoma. Anticancer Res. 2013;33(12):5611–6.
Xu LZ, Li SS, Zhou W, Kang ZJ, Zhang QX, Kamran M, et al. p62/SQSTM1 enhances breast cancer stem-like properties by stabilizing MYC mRNA. Oncogene. 2017;36(3):304–17.
Tang DY, Ellis RA, Lovat PE. Prognostic impact of autophagy biomarkers for cutaneous melanoma. Front Oncol. 2016;6:236.
Park JM, Huang S, Wu TT, Foster NR, Sinicrope FA. Prognostic impact of Beclin 1, p62/sequestosome 1 and LC3 protein expression in colon carcinomas from patients receiving 5-fluorouracil as adjuvant chemotherapy. Cancer Biol Ther. 2013;14(2):100–7.
Wang X, He H, Zhang K, Peng W. The expression of TSSC3 and its prognostic value in patients with osteosarcoma. Biomed Pharmacother. 2016;79:23–6.
Moad AI, Muhammad TS, Oon CE, Tan ML. Rapamycin induces apoptosis when autophagy is inhibited in T-47D mammary cells and both processes are regulated by Phlda1. Cell Biochem Biophys. 2013;66(3):567–87.
Grassi G, Di Caprio G, Santangelo L, Fimia GM, Cozzolino AM, Komatsu M, et al. Autophagy regulates hepatocyte identity and epithelial-to-mesenchymal and mesenchymal-to-epithelial transitions promoting snail degradation. Cell Death Dis. 2015;6:e1880.
Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, et al. Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci U S A. 2014;111(25):9241–6.
Hollomon MG, Gordon N, Santiago-O’Farrill JM, Kleinerman ES. Knockdown of autophagy-related protein 5, ATG5, decreases oxidative stress and has an opposing effect on camptothecin-induced cytotoxicity in osteosarcoma cells. BMC Cancer. 13(1):500.
Pattingre S, Espert L, Biard-Piechaczyk M, Codogno P. Regulation of macroautophagy by mTOR and Beclin 1 complexes. Biochimie. 2008;90(2):313–23.
Sakata N, Yamaguchi Y, Chen Y, Shimoda M, Yoshimatsu G, Unno M, et al. Pleckstrin homology-like domain family a, member 3 (PHLDA3) deficiency improves islets engraftment through the suppression of hypoxic damage. PLoS One. 2017;12(11):e0187927.
The authors thank Professor Zheng-Xue Quan for his guidance of this study. We thank the Institute of Central Labortory of Xinqiao Hospital for providing parts of the experimental apparatus. We would like to thank the native English speaking scientists of Elixigen Company (Huntington Beach, California) for editing our manuscript. We also thank Ms. Xing Rong, Mr. Shen-Jia Ye and Ms. Ya-Li Wang (Xinqiao Hospital, Third Military Medical University) for their assistance with immunohistochemistry techniques. In addition, Guo-Sheng Zhao and Qiao Zhang especially wish to thank their daughter Xuan-Ya Zhao who has given them powerful spiritual support.
This work was supported by the National Natural Science Foundation of China (NSFC) [grant number 81372864 and 81672653] and the Chongqing Science and Technology Committee Foundation, China [grant number cstc2015jcyj BX0067].
Availability of data and materials
Most of the datasets supporting the conclusions of this article are included within this article and the additional files. The datasets used or analyzed during the current study are available on reasonable request.
Ethics approval and consent to participate
All human tissues experiments were approved by the Institutional Ethics Committee of Third Military Medical University. Written informed consent form for the experimental studies was obtained from the patients or their guardians. All the animal care and experimental procedures were conformed to the Institutional Animal Care and Use Committee of Xinqiao Hospital, Third Military Medical University according to the Guide for the Care Use of Laboratory Animals.
Consent for publication
Written informed consent for publication was obtained from the participants or their guardians at the time of admission, with which the tissue samples might be used for scientific research but did not relate to individual privacy.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Materials and Methods. (RTF 91 kb)
Supplementary Tables. Table S1. shRNA target sequence used in the experiments. Table S2. Primers used for qRT-PCR in this study. Table S3. Correlation between TSSC3 expression and ATG5 or P62 expression in patients with osteosarcoma. Table S4. Univariate Cox proportional hazard regression analysis for overall survival in patients with osteosarcoma. Table S5. Correlations between ATG5 expression and the metastasis or recurrence of positive-TSSC3 expression osteosarcoma. (RTF 137 kb)
Supplementary Figures. Figure S1. Immunohistochemistry staining of TSSC3, ATG5 and P62 in human benign bone and soft tissue tumors and osteosarcoma tissues. Figure S2. TSSC3 overexpression enhances ATG5 and BECN1 expression and the block autophagic flux function of chloroquine. Figure S3. TSSC3 overexpression inhibited cells growth in vitro and autophagy suppression attenuates OverTSSC3-induced apoptosis in SaOS2 cells but not in MTF cells. Figure S4. Downregulation of ATG5 restrained the autophagy promotion and reversed the inhibition of osteosarcoma tumorigenicity caused by TSSC3 overexpression in vivo. Figure S5. The quantification of western blot results in Figure 5e and f. Figure S6. Immunocytochemical analysis of metastatic lung nodules and Kaplan–Meier overall survival curves from the in vivo metastasis model. Figure S7. The quantification of western blot results in Figure 7. (DOCX 7590 kb)
About this article
Cite this article
Zhao, Gs., Gao, Zr., Zhang, Q. et al. TSSC3 promotes autophagy via inactivating the Src-mediated PI3K/Akt/mTOR pathway to suppress tumorigenesis and metastasis in osteosarcoma, and predicts a favorable prognosis. J Exp Clin Cancer Res 37, 188 (2018). https://doi.org/10.1186/s13046-018-0856-6